Patents by Inventor Craig A. Zificsak

Craig A. Zificsak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES
    Publication number: 20160368874
    Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Inventors: Nadine C. Becknell, Reddeppa Reddy Dandu, Bruce D. Dorsey, Dimitar B. Gotchev, Robert L. Hudkins, Linda Weinberg, Craig A. Zificsak, Allison L. Zulli
  • Substituted aromatic sulfur compounds and methods of their use
    Patent number: 9475766
    Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: October 25, 2016
    Assignees: Cephalon, Inc., University of Utah Research Foundation, University of Hawaii
    Inventors: Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20160102094
    Abstract: The present application provides a compound of formula (1) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Applicants: IGNYTA, INC., Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R.A. Roffey, Nathaneil J.T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • Azaquinazoline Inhibitors Of Atypical Protein Kinase C
    Publication number: 20150274720
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Application
    Filed: March 25, 2015
    Publication date: October 1, 2015
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel JT Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R.A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20140113882
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 24, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J.T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
  • Substituted Aromatic Sulfur Compounds and Methods of Their Use
    Publication number: 20140005175
    Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
    Type: Application
    Filed: August 26, 2013
    Publication date: January 2, 2014
    Applicants: Cephalon, Inc., University of Utah Research Foundation, University of Hawaii
    Inventors: Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
  • Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
    Patent number: 8552186
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: October 8, 2013
    Assignee: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry J. Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce D. Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph Lisko, Rong-qiang Liu, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
  • Pyrrolotriazines as ALK and JAK2 inhibitors
    Patent number: 8471005
    Abstract: The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: June 25, 2013
    Assignee: Cephalon, Inc.
    Inventors: Henry J. Breslin, Sankar Chatterjee, James L. Diebold, Bruce D. Dorsey, Derek D. Dunn, Diane E. Gingrich, Greg A. Hostetler, Robert L. Hudkins, Rachael Hunter, Kurt A. Josef, Joseph Lisko, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Babu G. Sundar, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Linda Weinberg, Gregory J. Wells, Craig A. Zificsak
  • Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
    Publication number: 20120165519
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: March 6, 2012
    Publication date: June 28, 2012
    Applicant: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph G. Lisko, Rong-qiang Liu, Eugen Mesaros, Karen Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
  • Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
    Patent number: 8148391
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: April 3, 2012
    Assignee: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph G. Lisko, Rong-Qiang Liu, Eugen Florin Mesaros, Karen Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
  • PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS
    Publication number: 20120028919
    Abstract: The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: June 15, 2011
    Publication date: February 2, 2012
    Applicant: CEPHALON, INC.
    Inventors: Henry J. Breslin, Sankar Chatterjee, James L. Diebold, Bruce D. Dorsey, Derek D. Dunn, Diane E. Gingrich, Greg A. Hostetler, Robert L. Hudkins, Rachael Hunter, Kurt A. Josef, Joseph Lisko, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Babu G. Sundar, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Linda Weinberg, Gregory J. Wells, Craig A. Zificsak
  • Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
    Patent number: 8080561
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: December 20, 2011
    Assignee: Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Jay P. Theroff, Linda Weinberg, Craig A. Zificsak
  • PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS
    Publication number: 20110160204
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Application
    Filed: February 25, 2011
    Publication date: June 30, 2011
    Applicant: CEPHALON, INC.
    Inventors: Bruce D. Dorsey, Karen L. Milkiewicz, Douglas A. Pippin, Jay P. Theroff, Ted Underiner, Linda Weinberg, Craig A. Zificsak
  • Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors
    Patent number: 7919502
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: April 5, 2011
    Assignee: Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Douglas A. Pippin, Jay P. Theroff, Craig A. Zificsak
  • PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS
    Publication number: 20100048576
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Application
    Filed: September 24, 2009
    Publication date: February 25, 2010
    Applicant: CEPHALON, INC.
    Inventors: Bruce D. Dorsey, Karen L. Milkiewicz, Douglas A. Pippin, Jay P. Theroff, Ted Underiner, Linda Weinberg, Craig A. Zificsak
  • Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
    Patent number: 7601716
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: October 13, 2009
    Assignee: Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Karen L. Milkiewicz, Douglas A. Pippin, Jay P. Theroff, Ted Underiner, Linda Weinberg, Craig A. Zificsak
  • FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
    Publication number: 20090221555
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: October 23, 2007
    Publication date: September 3, 2009
    Applicants: Cephalon, Inc., Pharmacopeia Drug Discovery, Inc.
    Inventors: Gulzar Ahmed, Adolph Bohnstedt, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Koc-Kan Ho, Keith S. Learn, Joseph G. Lisko, Rong-qiang Liu, Eugen Mesaros, Karen Milkiewicz, Gregory R. Ott, Jonathan Parrish, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Jason C. Wagner, Linda Weinberg, Gregory J. Wells, Ming You, Craig A. Zificsak
  • Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors
    Publication number: 20080032972
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Application
    Filed: April 30, 2007
    Publication date: February 7, 2008
    Applicant: Cephalon, Inc.
    Inventors: Bruce Dorsey, Karen Milkiewicz, Douglas Pippin, Jay Theroff, Ted Underiner, Linda Weinberg, Craig Zificsak
  • Method of synthesis of azole-containing amino acids
    Patent number: 7259263
    Abstract: The invention relates to methods of synthesizing 2-substituted azole compunds of formula (I): The invention is also relates to compounds of formula (I) and to intermediate compounds in the synthesis method.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: August 21, 2007
    Assignee: Jansen Pharmaceutica N.V.
    Inventors: Dennis J. Hlasta, Craig A. Zificsak
  • Method of synthesis of azole-containing amino acids
    Publication number: 20070004728
    Abstract: The invention relates to methods of synthesizing 2-substituted azole compunds of formula (I): The invention is also relates to compounds of formula (I) and to intermediate compounds in the synthesis method.
    Type: Application
    Filed: June 29, 2005
    Publication date: January 4, 2007
    Inventors: Dennis Hlasta, Craig Zificsak